WB6Dim-LTSA: Can Workplace Well-Being Scores Predict Collective Absenteeism?
WB6Dim-LTSA
Predictive Value of the Adaptive Load Index (ICA) Derived From the WB6Dim Instrument on Collective Absenteeism Rates at a 6-Month Horizon: A Prospective Multicenter Cohort Study
1 other identifier
observational
2,000
1 country
1
Brief Summary
This prospective multicenter cohort study evaluates the predictive value of the Adaptive Load Index (ICA), a composite indicator derived from the WB6Dim well-being instrument, on long-duration sick leave (≥ 30 days) in French companies at a 6-month horizon. In France, 7% of sick leave episodes (those exceeding 6 months) account for 45% of total sickness benefit expenditure (Cour des Comptes 2024). Group disability insurance charges rose +24.4% in 2024 (France Assureurs 2025). Critically, a substantial proportion of long-duration sick leave occurs without prior escalation in administrative absence data - the 'cliff effect' - where presenteeism masks progressive deterioration (Gustafsson \& Marklund 2011). Prediction models based solely on absence history plateau at AUC 0.65 for cumulative days (Roelen 2013), while composite psychometric instruments reach C-index 0.73-0.74 (Airaksinen et al. 2018, SJWEH). The WB6Dim is a validated 28-item psychometric tool measuring 9 dimensions of workplace well-being (NCT07301879, NCT07433764; test-retest ICA .904). The ICA classifies respondents into 4 adaptive load levels. Aggregated at the company level, the ICA distribution may detect deterioration during the presenteeism window, before costly sick leave materializes. The study collects 4 WB6Dim assessments over 6 months alongside company-level absence data stratified by duration (2024-2026) and individual self-reported absence data (duration and episode count). Six pre-registered hypotheses test whether ICA predicts long-duration leave, including an exploratory hypothesis targeting companies with no prior absence signal but degraded well-being scores.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2026
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 17, 2026
CompletedFirst Posted
Study publicly available on registry
May 26, 2026
CompletedStudy Start
First participant enrolled
June 1, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 15, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
November 30, 2026
May 26, 2026
May 1, 2026
6 months
May 17, 2026
May 17, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Company-level incidence rate of sick leave episodes ≥ 30 days over 6 months, as measured from aggregated HR records
Company-level incidence of sick leave episodes lasting 30 days or more, measured from aggregated HR data provided by each participating company for the period June-November 2026. This threshold marks the transition from short-term to long-term sickness absence in the French social security system and is associated with sharply reduced return-to-work probability.
6 months post-enrollment
Secondary Outcomes (6)
Company-level incidence rate of sick leave episodes ≥ 90 days over 6 months, as measured from aggregated HR records
6 months post-enrollment
Number of employees with ≥ 3 distinct absence episodes within 6 months per company, as measured from aggregated HR records
6 months post-enrollment
Self-reported cumulative absence duration and episode count, as measured by WB6Dim questionnaire items
Baseline, 3 months, and 6 months post-enrollment
Change in collective ICA distribution from baseline to 3 months as a predictor of sick leave ≥ 30 days between 3 and 6 months
Baseline and 3 months (predictor); 3 to 6 months post-enrollment (outcome)
Change in predictive model AUC when adding DAE profile distribution to the ICA-based model for sick leave ≥ 30 days
6 months post-enrollment
- +1 more secondary outcomes
Study Arms (1)
Multi-company workforce cohort
Single-cohort design. All participants receive the same observational protocol: 4 WB6Dim assessments over 6 months. The predictive analysis is conducted at the company level, comparing companies above versus below the sample median of collective critical ICA proportion at T0. No group assignment is made at the individual level. Stratification is performed post-hoc based on observed ICA distributions.
Eligibility Criteria
Employees of French companies with 50 or more employees, recruited through employer participation agreements. Companies are sourced through occupational health networks and direct outreach. All employees meeting inclusion criteria within participating companies are eligible regardless of job type, contract status, or health condition.
You may qualify if:
- Employee of a participating French company (≥ 50 employees)
- Age 18 years or older
- Access to a smartphone or computer to complete the digital questionnaire
- Electronic informed consent provided at baseline
You may not qualify if:
- Refusal to participate or withdrawal of consent
- Inability to complete the questionnaire in French
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Clover Linklead
Study Sites (1)
Clover Link
Bandol, 83150, France
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Frédérique RETORNAZ, MD, PhD
European Hospital, Unit of Care and Research in Internal Medicine and Infectious Diseases.
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 17, 2026
First Posted
May 26, 2026
Study Start
June 1, 2026
Primary Completion (Estimated)
November 15, 2026
Study Completion (Estimated)
November 30, 2026
Last Updated
May 26, 2026
Record last verified: 2026-05
Data Sharing
- IPD Sharing
- Will not share
Individual participant data will not be shared. The study analyzes company-level aggregated indicators only. No individual diagnosis or prognosis is delivered. Sharing individual-level data would conflict with GDPR requirements and the anonymization commitments made to participants and employers in the informed consent. De-identified, aggregated company-level datasets may be made available to qualified researchers upon reasonable request and approval by the data protection officer.